Archive

Weekly Round UpWeekly Round Up
GLP-1s Go Prime Time, Sub-$50M M&A Rebounds, and 67% Back Specialty Care

GLP-1s Go Prime Time, Sub-$50M M&A Rebounds, and 67% Back Specialty Care

Pharma pushes weight-loss drugs to the mass market and small deals clear 4 in 60 days, while India’s patient satisfaction drops to 46%.

SurveysSurveys
Where Healthcare M&A Is Most Likely to Hold Up in 2026

Where Healthcare M&A Is Most Likely to Hold Up in 2026

Healthcare dealmaking may be slower and more selective, but it’s far from stalled.

Weekly Round UpWeekly Round Up
Who’s Winning in Healthcare Now: AI Megadeals, Staffing Giants & Telehealth Choices

Who’s Winning in Healthcare Now: AI Megadeals, Staffing Giants & Telehealth Choices

Deal count surges in healthcare AI and compliance tightens on staffing, while reliability drives 66% of telehealth platform decisions.

Long Form ArticleLong Form Article
AI Is Outgrowing the Mega-Deal

AI Is Outgrowing the Mega-Deal

For years, healthcare AI funding followed a familiar arc: bigger rounds, fewer companies, and a steady march toward “mega-deals.” In 2025, that narrative is starting to bend.

Weekly Round UpWeekly Round Up
AstraZeneca’s $15B Bet, €4bn Pharma Exit, and 36% Skip Care

AstraZeneca’s $15B Bet, €4bn Pharma Exit, and 36% Skip Care

AstraZeneca commits $15B to China and Permira eyes a €4bn sale of Neuraxpharm, while high costs force 36% of rural U.S. patients to forgo treatment.

Weekly Round UpWeekly Round Up
$9.9M HIPAA Fines, 50% Integration Pain, 78% Betting On AI

$9.9M HIPAA Fines, 50% Integration Pain, 78% Betting On AI

78% of leaders turn to AI for efficiency and $9.9M in HIPAA fines signals tougher enforcement, while integration complexity stalls virtual care for 50%.

Long Form ArticleLong Form Article
Cost Containment in 2026: Pharma’s AI-Powered Reset

Cost Containment in 2026: Pharma’s AI-Powered Reset

Facing tighter margins and rising R&D costs, life sciences executives are prioritizing cost discipline like never before.

Weekly Round UpWeekly Round Up
Healthcare M&A Under Pressure, Gavi Funding at Risk, and the Rise of Personalized Medicine

Healthcare M&A Under Pressure, Gavi Funding at Risk, and the Rise of Personalized Medicine

The U.S. conditions Gavi funding on thimerosal elimination and North America holds 45% of the personalized medicine market, while integration risk tops M&A concerns.

SurveysSurveys
What Will Really Slow Healthcare M&A in the Next 12 Months?

What Will Really Slow Healthcare M&A in the Next 12 Months?

Healthcare dealmaking isn’t short on capital—or targets. What it is short on is certainty.

Weekly Round UpWeekly Round Up
Healthcare’s New Reality: $191B Deals, 61% More M&A, Rising Scrutiny

Healthcare’s New Reality: $191B Deals, 61% More M&A, Rising Scrutiny

Digital health funding rebounds 35% and 74% cite innovation as the top cost driver, while regulators target pharmacy supply chains.

Research Deep DiveResearch Deep Dive
Healthcare Private Equity in 2025

Healthcare Private Equity in 2025

How capital discipline, operational execution, and sector specialization are reshaping healthcare investing—and setting the agenda for 2026

Weekly Round UpWeekly Round Up
FDA–EMA Alignment, FemTech’s Regional Divide, and a $14.5B MedTech Bet

FDA–EMA Alignment, FemTech’s Regional Divide, and a $14.5B MedTech Bet

Boston Scientific acquires Penumbra for $14.5B and North America leads FemTech with 39% market share, while regulators set joint AI principles.

FirstBack
678910111213
Next Last